The present invention relates to agents that modulate CoAA expression and/or activity and the use thereof for the treatment of diseases. Said agents are preferably selected from the group consisting of CoAA or CoAM expression inhibitors, RBM14 splicing modulators, agents which interfere or promote class I HDAC recruitment by CoAA and their combinations. Said agents are mainly intended for the treatment of viral diseases and/or cancer.